The ZnT8 antibody test detects autoantibodies against zinc transporter 8, a beta-cell membrane protein that loads zinc into insulin secretory granules. It is positive in 60 to 80 percent of new-onset type 1 diabetes and is particularly valuable because it identifies some T1D cases negative for both GAD-65 and IA-2. Together with GAD-65 and IA-2, ZnT8 forms the modern three-antibody panel that detects roughly 95 percent of autoimmune diabetes.
What ZnT8 Is and Why It Matters
ZnT8 (zinc transporter 8, gene SLC30A8) is a protein that sits in the membrane of beta-cell secretory granules and pumps zinc ions from the cytoplasm into the granule lumen. Zinc is essential for insulin to crystallize into the dense hexameric form stored in mature granules; without ZnT8, the insulin storage process is disrupted.
Because ZnT8 is highly expressed and largely specific to pancreatic beta cells, it is a natural autoimmune target in type 1 diabetes. The Wenzlau group’s 2007 discovery that ZnT8 autoantibodies are present in a majority of new-onset T1D patients filled an important diagnostic gap — many patients with classic clinical T1D had previously tested negative for all known autoantibodies (GAD-65, IA-2, anti-insulin, islet cell antibodies) and were labeled “antibody-negative T1D.” The ZnT8 test reclassified roughly half of these cases.
Sensitivity by Population
| Population | ZnT8 positivity rate | Notes |
|---|---|---|
| New-onset pediatric type 1 diabetes | 60 to 80 percent | Comparable to GAD-65 and IA-2 |
| New-onset adult type 1 diabetes | 50 to 70 percent | Higher than IA-2 in adults |
| LADA | 10 to 30 percent | Lower than GAD-65 in this group |
| “Antibody-negative” T1D (GAD-65 and IA-2 negative) | About 26 percent | Major reason to add ZnT8 to the panel |
| Long-standing T1D (5+ years) | 20 to 30 percent | Titers decline similar to IA-2 |
| Type 2 diabetes | Less than 2 percent | Highly specific |
| First-degree relatives of T1D | 2 to 4 percent | Used in TrialNet panel |
| General population | Less than 1 percent | Very specific marker |
When the ZnT8 Test Is Ordered
| Clinical situation | Why ZnT8 helps |
|---|---|
| New-onset diabetes with negative GAD-65 and IA-2 | Catches roughly 26 percent of those otherwise classified as antibody-negative |
| Standard T1D autoantibody panel at diagnosis | Increases overall panel sensitivity from 90 percent to about 95 percent |
| LADA evaluation in adults | Lower yield than GAD but still useful |
| TrialNet relative screening | Part of the validated panel |
| Pediatric diabetes diagnosis | Standard in modern pediatric T1D workup |
| Pre-pancreas/islet transplant evaluation | Comprehensive antibody documentation |
Reference Ranges and Interpretation
| Titer | Range (typical) | Interpretation |
|---|---|---|
| Negative | Less than 15 U/mL | No detectable ZnT8 autoantibodies (lab-dependent) |
| Borderline | 15 to 25 U/mL | Repeat in 4 to 8 weeks; correlate with other antibodies |
| Low positive | 25 to 100 U/mL | Supports autoimmune diabetes diagnosis |
| Moderate positive | 100 to 500 U/mL | Strong evidence of beta-cell autoimmunity |
| High positive | Greater than 500 U/mL | Aggressive autoimmunity; rapid beta-cell loss possible |
Cutoffs and units vary by laboratory and assay (radiobinding assay versus ECLIA). Always read against the reporting lab’s own reference range, and consider repeating borderline values on the same platform.
How the Test Is Performed
- Sample: serum from a routine venous blood draw
- Fasting required? No — antibody levels are stable across the day
- Assay platforms: radiobinding assay historically; now mostly ECLIA and ELISA. Some labs measure antibodies against multiple ZnT8 variants (CW, CR, CQ at amino acid 325) for higher sensitivity.
- Turnaround: typically 5 to 14 days
- Cost: 80 to 250 dollars self-pay; usually covered with appropriate indication
- Bundled panels: most labs sell GAD-65 + IA-2 + ZnT8 as a “diabetes autoantibody panel” at a modest discount versus separate ordering
The ZnT8 Genetic Polymorphism
ZnT8 has a common polymorphism at amino acid position 325 — the residue can be tryptophan (W), arginine (R), or glutamine (Q). Some patients produce antibodies that recognize only one variant; others recognize multiple variants. Modern assays use a fusion protein covering all three variants to maximize sensitivity. If your ZnT8 result is reported with multiple subtypes, that simply reflects this assay design.
ZnT8 in the Modern T1D Antibody Panel
| Panel composition | Sensitivity for new-onset T1D | Specificity |
|---|---|---|
| GAD-65 alone | 60 to 80 percent | About 95 percent |
| IA-2 alone | 30 to 60 percent | Greater than 98 percent |
| ZnT8 alone | 60 to 80 percent | Greater than 98 percent |
| GAD-65 + IA-2 | About 90 percent | About 99 percent |
| GAD-65 + IA-2 + ZnT8 | About 95 percent | Greater than 99 percent |
| Full TrialNet panel (+ anti-insulin) | 96 to 98 percent | Greater than 99 percent |
The marginal benefit of ZnT8 — about a 5 percentage point increase in T1D detection — is most impactful in the subset of patients otherwise miscategorized as antibody-negative or as type 2 diabetes. In a busy diabetes clinic, this can represent reclassification of meaningful numbers of patients per year.
ZnT8 in T1D Risk Stratification
In the staged model of T1D (autoantibody positive → dysglycemia → clinical diabetes), ZnT8 acts like IA-2 — it tends to appear after GAD-65 or anti-insulin in the natural history. The pattern of antibodies positive matters as much as the count:
- Single antibody positive (any one of GAD, IA-2, ZnT8, anti-insulin): 10 to 20 percent 5-year progression risk
- Two antibodies positive (any pair): 40 to 60 percent 5-year risk
- Three or four antibodies positive: 70 to 80 percent 5-year risk
- ZnT8 positivity especially correlates with rapid progression when combined with IA-2.
Limitations and Pitfalls
- Newer assay variability: ZnT8 testing was standardized later than GAD or IA-2; inter-lab agreement is improving but still imperfect.
- Polymorphism variability: some older assays missed antibodies against the Q325 variant. Confirm your lab uses the modern multi-variant fusion protein.
- Lower yield in long-standing diabetes: like IA-2, ZnT8 titers fall faster than GAD over the years following diagnosis.
- Not a stand-alone diabetes diagnostic: always confirm diabetes with A1C, fasting glucose, or OGTT.
- Negative does not exclude T1D: a small fraction of T1D is truly antibody-negative; pair ZnT8 with GAD-65 and IA-2.
- Borderline results: repeat in 4 to 8 weeks before drawing major conclusions.
What Happens After a Positive Result
- Review the rest of the panel (GAD-65, IA-2, anti-insulin) and count total positives.
- Check fasting and stimulated c-peptide for residual beta-cell function.
- Confirm or revise the diabetes type label (T1D, LADA, or T2D).
- In an at-risk relative who is not yet diabetic, refer to TrialNet or a specialty center for monitoring.
- In established diabetes, adjust treatment — earlier insulin consideration in confirmed T1D/LADA; avoid sulfonylureas.
- Counsel on monitoring for ketosis and DKA, especially during illness.
Related Reading
See our broader guides on detection of prediabetes, GAD-65 antibody testing, IA-2 antibody testing, islet cell antibodies, and c-peptide testing.
The Bottom Line
The ZnT8 antibody test is the newest member of the standard type 1 diabetes autoantibody panel, positive in 60 to 80 percent of new-onset T1D and uniquely valuable because it captures roughly a quarter of cases negative for both GAD-65 and IA-2. Adding ZnT8 to the panel pushes total T1D autoantibody detection from about 90 percent to roughly 95 percent. The test is well-established at major commercial labs and is part of TrialNet relative screening. Order ZnT8 as part of any new diabetes evaluation where autoimmune diabetes is on the differential, and especially when GAD-65 and IA-2 are negative but clinical suspicion remains high. Talk to your endocrinologist about whether ZnT8 testing fits your situation.
